ANTHRAX FUSION PROTEINS, COMPOSITIONS AND USES THEREOF
    1.
    发明申请
    ANTHRAX FUSION PROTEINS, COMPOSITIONS AND USES THEREOF 审中-公开
    ANTHRAX融合蛋白,组合物及其用途

    公开(公告)号:WO2008152655A1

    公开(公告)日:2008-12-18

    申请号:PCT/IN2008/000369

    申请日:2008-06-11

    CPC classification number: C07K14/32 A61K39/00 A61K39/07 C07K2319/55

    Abstract: The present invention relates to anthrax recombinant fusion proteins, process of preparation of such proteins and compositions thereof. Particularly the recombinant fusion proteins of the present invention comprise a native Edema factor protein (EF) or mutated Edema factor protein (EFm) or truncated Edema factor protein (EFn) and a native or mutated or mature Protective Antigen (PA) optionally with a linker wherein the linker is optionally a native Lethal factor protein (LF) or mutated Lethal factor protein (LFm) or truncated Lethal factor protein (LFn). Further, provided are nucleic acids encoding the DNA construct of the present invention. The compositions of the present invention may be useful as a pre-exposure and post-exposure prophylactic and/or therapeutic vaccine against anthrax.

    Abstract translation: 本发明涉及炭疽重组融合蛋白,这种蛋白质的制备方法及其组合物。 特别地,本发明的重组融合蛋白包含天然水肿因子蛋白(EF)或突变的水肿因子蛋白(EFm)或截短的水肿因子蛋白(EFn)和天然的或突变的或成熟的保护性抗原(PA),任选地具有接头 其中所述接头任选是天然致死因子蛋白(LF)或突变的致死因子蛋白(LFm)或截短的致死因子蛋白(LFn)。 此外,提供了编码本发明的DNA构建体的核酸。 本发明的组合物可用作针对炭疽的暴露前和暴露后的预防和/或治疗性疫苗。

Patent Agency Ranking